Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta

Journal of Immunological Methods

Volumn 321, Issue 1-2, 2007, Pages 19-31

  Bertolotto, A ^a   Sala, A ^a   Caldano, M ^a   Capobianco, M ^a   Malucchi, S ^a   Marnetto, F ^a   Gilli, F ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GB 23 902 531; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HUMAN INTERFERON; INTERFERON BETA SERINE; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BIOASSAY; BLOOD SAMPLING; CALIBRATION; CELL DENSITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

ANTIBODIES; BIOLOGICAL ASSAY; BIOLOGICAL RESPONSE MODIFIERS; CALIBRATION; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENCEPHALOMYOCARDITIS VIRUS; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UP-REGULATION;

ORTHOMYXOVIRIDAE;

EID: 33947322141     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2006.12.012     Document Type: Article

References (39)

1. Antonelli, G., Simeoni, E., Bagnato, F., Pozzilli, C., Turriziani, O., Tesoro, R., Di Marco, P., Gasperini, C., Fieschi, C., Dianzani, F., 1999. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J. Neurol. Sci. 15;168(2): 131.
2. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., and Mutani R. Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48 (2000) 95
3. Bertolotto A., Gilli F., Sala A., Audano L., Castello A., Magliola U., Melis F., and Giordana M.T. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods 256 1-2 (2001) 141
4. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., Milano E., Melis F., and Giordana M.T. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry 73 (2002) 148
5. Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., Melis F., Marnetto F., Lindberg R.L.P., Bottero R., and Bertolotto A. Persistent neutralizing antibodies abolish the interferonβ bioavailability in MS patients. Neurology 60 (2003) 634
6. Bertolotto A., Sala A., Malucchi S., Marnetto F., Caldano M., Di Sapio A., Capobianco M., and Gilli F. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry 75 (2004) 294
7. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307
8. Burckard H.J. Standardization and quality control of PCR analyses. Clin. Chem. Lab. Med. 38 (2000) 87-91
9. de Kok J.B., Roelofs R.W., Giesendorf B.A., Pennings J.L., Waas E.T., Feuth T., Swinkels D.W., and Span P.N. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab. Invest. 85 (2005) 154
10. Deisenhammer F., Reindel M., Harvey J., Gasse T., Dilitz E., and Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52 (1999) 1239
11. Files J.G., Gray J.L., Do L.T., Foley W.P., Gabe J.D., Nestaas E., and Pungor Jr. E. A novel sensitive and selective bioassay for human type I interferons. J. Interferon Cytokine Res. 18 (1998) 1019
12. Francis G.S., Rice G.P.A., Alsop J.C., and for the PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65 (2005) 48
13. Gilli F., Bertolotto A., Sala A., Hoffmann F., Capobianco M., Malucchi S., Glass T., Kappos L., Lindberg R.L.P., and Leppert D. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 127 Pt 2 (2004) 259
14. Gilli F., Marnetto F., Stefanuto G., Rinaldi V., Farinazzo F., Malucchi S., Capobianco M., Caldano M., Sala A., and Bertolotto A. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol. Diagn. 8 3 (2004) 185
15. Greenbaum, D., Colangelo, C., Williams, K., Gerstein, M., 2003. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 4(9), 117(1-8).
16. Grossberg S.E., Kawade Y., Kohase M., and Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 21 (2001) 743
17. Hartung H.P., and Munschauer III F.E. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. J. Neurol. 251 Suppl 2 (2004) II40
18. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., and and The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39 (1996) 285
19. Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.P., Hohlfeld R., Xu J., Bennett D., Sandrock A., Goelz S., and European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40
20. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 119 (1986) 558
21. Kawade Y., Finter N., and Grossberg S.E. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 278 (2003) 127
22. Keene O.N. The log transformation is special. Stat. Med. 14 (1995) 811
23. Malucchi S., Sala A., Gilli F., Bottero R., Di Sapio A., Capobianco M., and Bertolotto A. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62 (2004) 2031
24. Mata J., Marguerat S., and Bahler J. Post-transcriptional control of gene expression: a genome-wide perspective. Trends Biochem. Sci. 30 9 (2005) 506
25. Pachner, A.R., 2003. Anti-IFNβ Antibodies in IFNβ-Treated MS Patients. Neurology 61;9(Suppl 5).
26. Pachner A.R., Narayan K., Price N., Hurd M., and Dail D. MxA gene expression analysis as an interferon-β bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol. Diagn. 7 1 (2003) 17
27. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. J. Neuroimmunol. 166 1-2 (2005) 180
28. Perini P., Calabrese M., Biasi G., and Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J. Neurol. 251 (2004) 305
29. Polman C., et al., for the European Study Group in Interferon β-1b in Secondary Progressive MS. Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology 60 (2003) 37
30. Pungor Jr. E., Files J.G., Gabe J.D., Do L.T., Foley W.P., Gray J.L., Nelson J.W., Nestaas E., Taylor J.L., and Grossberg S.E. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J. Interferon Cytokine Res. 18 (1998) 1025
31. Research Reference Reagent Note No 45. Freeze-dry human anti-human interferon-beta antibody reference catalog number G038-501-572. Research Resources Section, National Institute of Allergy and Infectious Diseases (1995), NIH, Bethesda, MD
32. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer Jr. F.E., Cookfair D.L., Simon J.H., Jacobs L.D., and and the Multiple Sclerosis Collaborative Research Group (MSCRG). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50 (1998) 1266
33. Runkel L., De Dios C., Karpusas M., Baker D., Li Z., Zafari M., Betzenhauser M., Muldowney C., Miller S., Redlich P.N., Grossberg S.E., Whitty A., and Hochman P.S. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J. Interferon Cytokine Res. 21 11 (2001) 931
34. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., Bendtzen K., and and the Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33
35. Sorensen P.S., et al., for the EFNS Task Force on Anti-IFN-β Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Eur. J. Neurol. 12 (2005) 817
36. The IFNB Multiple Sclerosis Study Group, and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277
37. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56 (2001) 1628
38. Vallittu A.-M., Halminen M., Peltoniemi J., Ilonen J., Julkunen I., Salmi A., Erälinna J.-P., and and the Finnish Beta-Interferon Study Group. Neutralizing antibodies reduce MxA protein induction in interferon beta-1a-treated MS patients. Neurology 58 (2002) 1786
39. WHO Expert Committee on Biological Standardisation. Thirty-Fifth Report. WHO Technical Report Series 725 (1985), World Health Organization, Geneva